ANAVEX 2-73 significantly reduced sound-triggered seizures in mice with Angelman syndrome, according to a preclinical-trial study. Its developer, Anavex Life Sciences, reported the results at the Antiepileptic Drug Trials XIV 2017 Conference  in North Miami Beach, May 17-19. The presentation was titled “ANAVEX 2-73,…
News
Ovid Therapeutics is conducting two clinical trials assessing its lead candidate OV101 for the treatment of adolescents and adults with Angelman syndrome. Both trials are currently enrolling participants. “Ovid has a clear strategy and business plan to build a neurology company focused on rare disorders of the brain,” Jeremy…
Recent Posts
- Angelman clinical trial enrolls children to test new treatment
- Angelman syndrome seizures are unpredictable, but we carry on
- $32.5M to advance rugonersen into late-stage testing for Angelman
- GTX-102 data show continued developmental gains in Angelman
- What standardized assessments miss about my son with Angelman
- Surgery usually corrects misaligned eyes in kids with Angelman, study finds
- The joys and challenges of disability equipment for children with Angelman
- Goals that matter most for our child living with Angelman syndrome
- Home videos may help doctors evaluate Angelman patient skills
- After hesitation, we finally took steps to address our son’s disrupted sleep